Bayer (FRA:BAYN) has been given a €85.00 ($98.84) price target by equities researchers at Barclays in a research note issued on Wednesday. The firm presently has a “buy” rating on the healthcare company’s stock. Barclays‘s target price suggests a potential upside of 34.92% from the stock’s previous close.
Several other equities analysts have also recently issued reports on the stock. Warburg Research set a €69.00 ($80.23) price target on shares of Bayer and gave the company a “neutral” rating in a research report on Wednesday. JPMorgan Chase & Co. set a €70.00 ($81.40) price target on shares of Bayer and gave the company a “neutral” rating in a research report on Wednesday. DZ Bank restated a “neutral” rating on shares of Bayer in a research report on Wednesday. Sanford C. Bernstein set a €86.00 ($100.00) price target on shares of Bayer and gave the company a “buy” rating in a research report on Wednesday. Finally, Goldman Sachs Group set a €78.00 ($90.70) price target on shares of Bayer and gave the company a “buy” rating in a research report on Wednesday. Nine equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of €87.83 ($102.12).
FRA BAYN traded down €6.70 ($7.79) on Wednesday, hitting €63.00 ($73.26). The company’s stock had a trading volume of 15,256,945 shares. Bayer has a 1-year low of €91.58 ($106.49) and a 1-year high of €123.82 ($143.98).
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Featured Article: Producer Price Index (PPI)
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.